Galidesivir

ArtNr	HY-18649A-10mg
Hersteller	MedChem Express
CAS-Nr.	249503-25-1
Menge	10 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.29
Citations	[1]Elfiky AA, et al. ICN-1229, Remdesivir, PSI-7977, Galidesivir, and GS 1278 against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020 Mar 25:117592.\|[2]Taylor R, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9(3):220-226.\|[3]Warren TK, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402-405.\|[4]Julander JG, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014;58(11):6607-6614. Antiviral Res. 2017 Mar 21;142:63-67.\|bioRxiv. 2025 January 29.\|Exp Ther Med. 2016 Sep;12(3):1812-1816. \|Microorganisms. 2021 Mar 31;9(4):734.\|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.\|Virology. 2023 May 26.\|Viruses. 2020 Jun 10;12(6):628.\|Antimicrob Agents Chemother. 2019 Feb 26;63(3):e02093-18.\|Antiviral Res. 2017 Mar 21;142:63-67.\|J AOAC Int. 2024 Jun 13:qsae047.\|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.
Smiles	O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BCX4430,Immucillin-A
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	DNA/RNA Synthesis; Filovirus; SARS-CoV
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	265.27
Product Description	Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM[1][2][3].
Manufacturer - Research Area	Infection
Solubility	H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Cell Cycle/DNA Damage
Clinical information	Phase 1

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-18649A-10mg-safety-datasheet.pdf